Rationale:
To track performance of intravitreal distribution of anti-VEGF-A (Bevazicumab-800CW) and
provide information about neovascularization and inflammation in Age-Related Macular
Degeneration (AMD), thereby predicting progression and optimizing treatment
Objective:
To determine the safety and feasibility of fluorescence imaging of the eye with the
fluorescent tracer bevacizumab-800CW for identification AMD with scanning laser angiography
Study design:
A non-randomized, non-blinded, prospective, single-center feasibility study.
Study population:
Patients group: patients with naïve wet AMD and wet AMD aged >60years old with current
treatment of anti-VEGF intravitreal.
Control group: patients with naïve wet AMD and wet AMD aged >60 years old with current
treatment of anti-VEGF intravitreal Optional control group: patients without eye disease and
currently included in another bevacizumab-800CW study.
Intervention (if applicable):
Intravenous injection of bevacizumab-800CW in the patient group and vedolizumab-800CW in the
control group.
Main study parameters/endpoints:
Safety and feasibility of the intravenous tracer bevacizumab-800CW in patients with naïve wet
AMD and wet AMD by observing the uptake in retinal, choroid and neovascular tissue.
Nature and extent of the burden and risks associated with participation, benefit and group
relatedness: No risk described in other (running) studies on intravenous injection with
bevacizumab-800 CW. Patients need to come back 48-72 hours after injection and the eye
measurements take about half an hour longer.
There is no benefit with participation.